Medincell (STU:MEB) Debt-to-EBITDA : -6.46 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Medincell Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medincell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €10.06 Mil. Medincell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €53.18 Mil. Medincell's annualized EBITDA for the quarter that ended in Sep. 2023 was €-9.79 Mil. Medincell's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -6.46.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medincell's Debt-to-EBITDA or its related term are showing as below:

STU:MEB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.83 Med: -2.2 Max: 5.49
Current: -3.13

During the past 8 years, the highest Debt-to-EBITDA Ratio of Medincell was 5.49. The lowest was -6.83. And the median was -2.20.

STU:MEB's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs STU:MEB: -3.13

Medincell Debt-to-EBITDA Historical Data

The historical data trend for Medincell's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Debt-to-EBITDA Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.61

-1.87

-2.82

-2.21

-2.19

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial										-2.22	-2.11	-2.19	-1.88	-6.46

Competitive Comparison of Medincell's Debt-to-EBITDA

For the Biotechnology subindustry, Medincell's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medincell's Debt-to-EBITDA falls into.

Medincell Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medincell's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(43.456	+	14.252)	/	-26.413
	=	-2.18

Medincell's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(10.055	+	53.175)	/	-9.79
	=	-6.46

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Medincell (STU:MEB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Medincell Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medincell's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (STU:MEB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (STU:MEB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

MEDCL:France MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (STU:MEB) Headlines

No Headlines